IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Wockhardt Poised for U.S. Drug Launch

1:20 PM MDT | June 13, 2007 | DR

Wockhardt (Mumbai), a pharmaceuticals and biotechnology company, has received tentative approval from the U.S. FDA to market terbinafine tablets in the U.S. Terbinafine is the generic version of Novartis’s branded drug Lamisil. The U.S. product patent for Lamisil expires on June 29. The U.S. market for terbinafine tablets, which are used to treat fungal infections, is estimated to be worth $680 million/year. “Our Wockhardt USA team is ready to embark on the launch of terbinafine the day the product patent expires,” says Habil Khorakiwala...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa